MXCT Stock Price, MaxCyte, Inc. Quote, Chart

Market Summary

USD4.66-0.14

Delayed

-2.92%

MXCT Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

MXCT Stock Price

View Fullscreen

MXCT RSI Chart

MXCT Valuation

Market Cap

487.2M

Price/Earnings (Trailing)

-13.32

Price/Sales (Trailing)

11.06

Price/Free Cashflow

-15.78

MXCT Price/Sales (Trailing)

MXCT Profitability

Operating Margin

93.35%

Return on Equity

-16.15%

Return on Assets

-14.18%

Free Cashflow Yield

-6.34%

MXCT Fundamentals

MXCT Revenue

Revenue (TTM)

44.1M

Rev. Growth (Yr)

32.25%

Rev. Growth (Qtr)

-27.59%

MXCT Earnings

Earnings (TTM)

-36.6M

Earnings Growth (Yr)

12.46%

Earnings Growth (Qtr)

-80.49%

Breaking Down MXCT Revenue

Last 7 days

-1.7%

Last 30 days

18.3%

Last 90 days

-1.3%

Trailing 12 Months

24.3%

How does MXCT drawdown profile look like?

MXCT Financial Health

Current Ratio

13.26

MXCT Investor Care

Shares Dilution (1Y)

1.45%

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	44.1M	0	0	0
2023	41.3M	40.7M	38.0M	41.3M
2022	39.0M	41.5M	42.0M	44.3M
2021	26.9M	28.9M	32.3M	33.9M
2020	0	23.1M	24.7M	26.2M
2019	0	0	0	21.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MaxCyte, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	johnston john joseph	acquired	10,710	2.142	5,000	-
Mar 26, 2024	johnston john joseph	sold	-22,025	4.405	-5,000	-
Mar 15, 2024	sandoval david i.	acquired	-	-	3,913	general counsel
Mar 15, 2024	ross thomas m.	acquired	-	-	25,000	evp, global sales & marketing
Mar 15, 2024	swirsky douglas j	acquired	-	-	81,250	chief financial officer
Feb 26, 2024	johnston john joseph	sold	-23,005	4.601	-5,000	-
Feb 26, 2024	johnston john joseph	acquired	10,710	2.142	5,000	-
Jan 26, 2024	johnston john joseph	sold	-25,585	5.117	-5,000	-
Jan 26, 2024	johnston john joseph	acquired	10,710	2.142	5,000	-
Dec 26, 2023	johnston john joseph	acquired	10,710	2.142	5,000	-

Which funds bought or sold MXCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-18.32	-87,720	234,992	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.83	-66,019	369,638	-%
May 16, 2024	Grandeur Peak Global Advisors, LLC	reduced	-61.83	-2,036,890	1,050,610	0.08%
May 15, 2024	HSBC HOLDINGS PLC	added	29.35	29,115	152,892	-%
May 15, 2024	Diametric Capital, LP	sold off	-100	-166,262	-	-%
May 15, 2024	SHERBROOKE PARK ADVISERS LLC	added	32.48	27,553	179,730	0.04%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	-263	2,163	-%
May 15, 2024	OPTIONS SOLUTIONS, LLC	new	-	156,078	156,078	0.09%
May 15, 2024	BARCLAYS PLC	reduced	-42.52	-316,000	332,000	-%
May 15, 2024	Aquatic Capital Management LLC	new	-	18,017	18,017	-%

Are Funds Buying or Selling MXCT?

Are funds buying MXCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MXCT

No. of Funds

Unveiling MaxCyte, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	integrated core strategies (us) llc	5.5%	5,743,954	SC 13G
Feb 14, 2024	casdin capital, llc	0%	0	SC 13G/A
Feb 14, 2024	cadian capital management, lp	5.5%	56,448	SC 13G
Feb 13, 2024	vanguard group inc	5.09%	5,282,108	SC 13G
Feb 01, 2024	integrated core strategies (us) llc	4.8%	5,011,710	SC 13G/A
Jan 26, 2024	blackrock inc.	8.0%	8,264,933	SC 13G/A
Nov 17, 2023	integrated core strategies (us) llc	5.6%	5,764,015	SC 13G
Feb 14, 2023	bamco inc /ny/	2.14%	2,182,982	SC 13G/A
Feb 13, 2023	sofinnova crossover i	4.5%	4,610,693	SC 13G/A
Jan 31, 2023	blackrock inc.	7.6%	7,733,213	SC 13G/A

Recent SEC filings of MaxCyte, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 01, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Mar 28, 2024	4	Insider Trading
Mar 25, 2024	SC 13G	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	10-K	Annual Report

Peers (Alternatives to MaxCyte, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

MaxCyte, Inc. News

Latest updates

MaxCyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-27.6%	11.00	16.00	8.00	9.00	9.00	12.00	11.00	10.00	12.00	10.00	10.00	7.00	6.00	9.00	7.00	5.00	-
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	1.00	0.00	-
Gross Profit	-29.5%	10.00	14.00	7.00	8.00	8.00	11.00	9.00	8.00	11.00	9.00	9.00	6.00	6.00	8.00	6.00	5.00	-
Operating Expenses	0.1%	22.00	22.00	21.00	21.00	21.00	18.00	17.00	17.00	15.00	14.00	12.00	11.00	12.00	10.00	9.00	8.00	-
S&GA Expenses	2.3%	7.00	7.00	7.00	6.00	6.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	-
R&D Expenses	14.3%	7.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	4.00	3.00	3.00	3.00	6.00	5.00	5.00	4.00	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	-	-
Net Income	-80.5%	-9.53	-5.28	-11.25	-10.51	-10.88	-4.81	-6.43	-8.26	-4.07	-4.87	-2.68	-4.42	-7.11	-2.65	-3.10	-3.00	-
Net Income Margin	9.6%	-0.83*	-0.92*	-0.98*	-0.80*	-0.74*	-0.53*	-0.56*	-0.48*	-0.41*	-0.56*	-0.52*	-0.60*	-0.59*	-0.45*	-	-	-
Free Cashflow	-17092.5%	-11.37	0.00	-8.96	-10.61	-5.88	-8.28	-9.40	-5.89	-9.69	-2.08	-2.13	-5.35	-4.95	-2.27	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-3.9%	258	268	267	271	282	287	286	290	291	284	278	93.00	52.00
Current Assets	-6.1%	179	190	214	237	246	252	252	258	266	270	270	85.00	45.00
Cash Equivalents	-52.2%	22.00	47.00	49.00	55.00	38.00	11.00	43.00	109	240	48.00	59.00	37.00	19.00
Inventory	-2.2%	12.00	12.00	13.00	11.00	10.00	9.00	8.00	8.00	7.00	5.00	4.00	4.00	4.00
Net PPE	-3.0%	23.00	24.00	24.00	24.00	25.00	24.00	23.00	21.00	13.00	8.00	7.00	5.00	5.00
Liabilities	-12.6%	32.00	36.00	33.00	30.00	34.00	33.00	32.00	33.00	29.00	21.00	14.00	14.00	19.00
Current Liabilities	-24.5%	13.00	18.00	17.00	13.00	17.00	15.00	17.00	18.00	16.00	16.00	13.00	13.00	12.00
Shareholder's Equity	-2.5%	226	232	233	241	248	254	254	257	262	263	264	79.00	33.00
Retained Earnings	-5.4%	-185	-175	-170	-159	-148	-137	-133	-126	-118	-114	-109	-106	-95.22
Additional Paid-In Capital	0.9%	411	407	403	399	396	391	386	383	380	376	373	185	128
Shares Outstanding	0.4%	104	104	104	103	103	102	102	102	101	101	87.00	83.00	-
Float	-	-	-	-	468	-	-	-	409	-	-	-	1,000	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-1176.1%	-10,564	982	-8,238	-10,104	-4,324	-6,086	-5,921	919	-3,694	-960	-690	-4,386	-4,642	-1,912	-830	-	-
Share Based Compensation	-15.7%	3,015	3,575	3,609	3,519	3,277	3,118	3,199	2,973	2,462	2,448	2,285	1,905	1,320	767	598	-	-
Cashflow From Investing	-247.8%	-14,396	-4,139	2,815	26,672	29,637	-27,095	-60,671	-131,853	194,797	-11,438	-162,345	-36,921	15,692	-376	-16,650	-	-
Cashflow From Financing	42.6%	703	493	37.00	157	1,457	1,226	444	326	893	1,207	184,586	27.00	48,899	91.00	262	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MXCT Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Unaudited Condensed Consolidated Statements of Operations
Revenue	$ 11,342	$ 8,576
Cost of goods sold	1,403	1,000
Gross profit	9,939	7,576
Operating expenses:
Research and development	6,678	6,047
Sales and marketing	7,365	6,296
General and administrative	7,103	7,499
Depreciation and amortization	1,068	912
Total operating expenses	22,214	20,754
Operating loss	(12,275)	(13,178)
Other income:
Interest income	2,749	2,296
Total other income	2,749	2,296
Loss before income taxes	(9,526)	(10,882)
Net loss	$ (9,526)	$ (10,882)
Basic net loss per share	$ (0.09)	$ (0.11)
Weighted average shares outstanding, basic	104,089,758	102,846,036

MXCT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 22,249	$ 46,506
Short-term investments, at amortized cost	135,264	121,782
Accounts receivable, net	5,991	5,778
Inventory	11,960	12,229
Prepaid expenses and other current assets	3,210	3,899
Total current assets	178,674	190,194
Investments, non-current, at amortized cost	45,031	42,938
Property and equipment, net	22,805	23,513
Right-of-use asset - operating leases	11,125	11,241
Other assets	295	388
Total assets	257,930	268,274
Current liabilities:
Accounts payable	1,674	743
Accrued expenses and other	6,502	11,269
Operating lease liability, current	825	774
Deferred revenue, current portion	4,476	5,069
Total current liabilities	13,477	17,855
Operating lease liability, net of current portion	17,815	17,969
Other liabilities	279	283
Total liabilities	31,571	36,107
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.01 par value; 400,000,000 shares authorized, 104,405,111 and 103,961,670 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,044	1,040
Additional paid-in capital	410,639	406,925
Accumulated deficit	(185,324)	(175,798)
Total stockholders' equity	226,359	232,167
Total liabilities and stockholders' equity	$ 257,930	$ 268,274

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

CEO	Mr. Douglas Arthur Doerfler
WEBSITE	https://maxcyte.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	125

MaxCyte, Inc. Frequently Asked Questions

What is the ticker symbol for MaxCyte, Inc.? What does MXCT stand for in stocks?

MXCT is the stock ticker symbol of MaxCyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MaxCyte, Inc. (MXCT)?

As of Fri May 17 2024, market cap of MaxCyte, Inc. is 487.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MXCT stock?

You can check MXCT's fair value in chart for subscribers.

What is the fair value of MXCT stock?

You can check MXCT's fair value in chart for subscribers. The fair value of MaxCyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MaxCyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MXCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MaxCyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether MXCT is over valued or under valued. Whether MaxCyte, Inc. is cheap or expensive depends on the assumptions which impact MaxCyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MXCT.

What is MaxCyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MXCT's PE ratio (Price to Earnings) is -13.32 and Price to Sales (PS) ratio is 11.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MXCT PE ratio will change depending on the future growth rate expectations of investors.